Efficacy of GLP-1-based Therapies on Metabolic Dysfunction-associated Steatotic Liver Disease and Metabolic Dysfunction-associated Steatohepatitis: A Systematic Review and Meta-analysis.

Wang Y, Zhou Y, Wang Z, Ni Y, Prud'homme GJ, Wang Q

The Journal of clinical endocrinology and metabolism1 Sept 2025Cited by 29 (Europe PMC)

PMID40489581DOI10.1210/clinem/dgaf336PepBankPUB-40489581

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study32

2 results from studies that gave the peptide. 2 results from people.

01HumanSystematic reviewEfficacy outcome
In a meta-analysis of RCTs in MASLD and MASH, retatrutide showed the most obvious effect on reducing liver fat content among the GLP-1RAs pooled.
In plain wordsIn a pooled analysis of trials in fatty liver disease, retatrutide showed the largest liver fat reduction among the GLP-1-based drugs.
Peptide
Retatrutide
Outcome
DecreaseLiver fat content reduction
Study
n: not reported in source
Comparator
Placebo or active agents
Outcome group
Liver fat and liver function · Liver
Studied dose
Dose not stated · median 24 weeks (pooled)As given in this study (human).
Source sentences
Summary
Overall, GLP-1RAs treatment for a median of 24 weeks demonstrated a significant reduction in LFC by 5.21%, with retatrutide displaying the most obvious treatment effects.
1 context sentence(design, population, supporting numbers)
Summary · context
We searched PubMed, Embase, and Cochrane Library databases to identify randomized controlled trials (RCTs) that compared GLP-1RAs with placebo or active agents with respect to the efficacy in patients with MASLD/MASH.
Report a problemFND-4048958101
02HumanSystematic reviewEfficacy outcome
In patients with MASLD or MASH, semaglutide showed the most obvious improvement in liver stiffness among the GLP-1RAs.
In plain wordsIn people with fatty liver disease, semaglutide showed the largest improvement in liver stiffness among the GLP-1 drugs compared.
Peptide
Semaglutide
Outcome
DecreaseLiver stiffness
Study
n: not reported in source
Outcome group
Liver fat and liver function · Liver
Studied dose
Dose not stated
Source sentences
Summary
GLP-1RAs also significantly improved liver stiffness, with semaglutide displaying the most obvious treatment effect.
2 context sentences(design, population, supporting numbers)
Summary · context
We searched PubMed, Embase, and Cochrane Library databases to identify randomized controlled trials (RCTs) that compared GLP-1RAs with placebo or active agents with respect to the efficacy in patients with MASLD/MASH.
Summary · context
Twenty-five RCTs involving 2600 patients who used GLP-1RAs including liraglutide, exenatide, dulaglutide, semaglutide, tirzepatide, efinopegdutide, survodutide, and retatrutide were included.
Report a problemFND-4048958129

Studies that did not test the peptide alone30

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

03HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In patients with MASLD or MASH, pooled GLP-1RAs (including semaglutide) reduced liver fat content by 5.21% over a median of 24 weeks.
In plain wordsIn people with fatty liver disease, GLP-1 drugs as a group, including semaglutide, lowered liver fat by 5.21%.
Peptide
Semaglutide
Outcome
DecreaseLiver fat content
Study
n = 2,600
Outcome group
Liver fat and liver function · Liver
Measurements
liver fat content reduction
5.21%
pooled GLP-1RAs
Source sentences
Summary
Overall, GLP-1RAs treatment for a median of 24 weeks demonstrated a significant reduction in LFC by 5.21%
2 context sentences(design, population, supporting numbers)
Summary · context
We searched PubMed, Embase, and Cochrane Library databases to identify randomized controlled trials (RCTs) that compared GLP-1RAs with placebo or active agents with respect to the efficacy in patients with MASLD/MASH.
Summary · context
Twenty-five RCTs involving 2600 patients who used GLP-1RAs including liraglutide, exenatide, dulaglutide, semaglutide, tirzepatide, efinopegdutide, survodutide, and retatrutide were included.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4048958102
04HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In patients with MASLD or MASH, pooled GLP-1RAs (including liraglutide) reduced liver fat content by 5.21% over a median of 24 weeks.
In plain wordsIn people with fatty liver disease, GLP-1 drugs as a group, including liraglutide, lowered liver fat by 5.21%.
Peptide
Liraglutide
Outcome
DecreaseLiver fat content
Study
n = 2,600
Outcome group
Liver fat and liver function · Liver
Measurements
liver fat content reduction
5.21%
pooled GLP-1RAs
Source sentences
Summary
Overall, GLP-1RAs treatment for a median of 24 weeks demonstrated a significant reduction in LFC by 5.21%
2 context sentences(design, population, supporting numbers)
Summary · context
We searched PubMed, Embase, and Cochrane Library databases to identify randomized controlled trials (RCTs) that compared GLP-1RAs with placebo or active agents with respect to the efficacy in patients with MASLD/MASH.
Summary · context
Twenty-five RCTs involving 2600 patients who used GLP-1RAs including liraglutide, exenatide, dulaglutide, semaglutide, tirzepatide, efinopegdutide, survodutide, and retatrutide were included.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4048958103
05HumanNot a test of Tirzepatide aloneSystematic reviewEfficacy outcome
In patients with MASLD or MASH, pooled GLP-1RAs (including tirzepatide) reduced liver fat content by 5.21% over a median of 24 weeks.
In plain wordsIn people with fatty liver disease, GLP-1 drugs as a group, including tirzepatide, lowered liver fat by 5.21%.
Peptide
Tirzepatide
Outcome
DecreaseLiver fat content
Study
n = 2,600
Outcome group
Liver fat and liver function · Liver
Measurements
liver fat content reduction
5.21%
pooled GLP-1RAs
Source sentences
Summary
Overall, GLP-1RAs treatment for a median of 24 weeks demonstrated a significant reduction in LFC by 5.21%
2 context sentences(design, population, supporting numbers)
Summary · context
We searched PubMed, Embase, and Cochrane Library databases to identify randomized controlled trials (RCTs) that compared GLP-1RAs with placebo or active agents with respect to the efficacy in patients with MASLD/MASH.
Summary · context
Twenty-five RCTs involving 2600 patients who used GLP-1RAs including liraglutide, exenatide, dulaglutide, semaglutide, tirzepatide, efinopegdutide, survodutide, and retatrutide were included.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4048958104
06HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In patients with MASLD or MASH, pooled GLP-1RAs (including semaglutide) significantly improved histological steatosis.
In plain wordsIn people with fatty liver disease, GLP-1 drugs as a group, including semaglutide, improved liver fat seen under the microscope.
Peptide
Semaglutide
Outcome
DecreaseHistological steatosis
Study
n = 2,600
Outcome group
Liver fat and liver function · Liver
Source sentences
Summary
GLP-1RAs treatment induced significant histological improvements in steatosis, hepatocellular ballooning, and lobular inflammation
2 context sentences(design, population, supporting numbers)
Summary · context
We searched PubMed, Embase, and Cochrane Library databases to identify randomized controlled trials (RCTs) that compared GLP-1RAs with placebo or active agents with respect to the efficacy in patients with MASLD/MASH.
Summary · context
Twenty-five RCTs involving 2600 patients who used GLP-1RAs including liraglutide, exenatide, dulaglutide, semaglutide, tirzepatide, efinopegdutide, survodutide, and retatrutide were included.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4048958105
07HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In patients with MASLD or MASH, pooled GLP-1RAs (including liraglutide) significantly improved histological steatosis.
In plain wordsIn people with fatty liver disease, GLP-1 drugs as a group, including liraglutide, improved liver fat seen under the microscope.
Peptide
Liraglutide
Outcome
DecreaseHistological steatosis
Study
n = 2,600
Outcome group
Liver fat and liver function · Liver
Source sentences
Summary
GLP-1RAs treatment induced significant histological improvements in steatosis, hepatocellular ballooning, and lobular inflammation
2 context sentences(design, population, supporting numbers)
Summary · context
We searched PubMed, Embase, and Cochrane Library databases to identify randomized controlled trials (RCTs) that compared GLP-1RAs with placebo or active agents with respect to the efficacy in patients with MASLD/MASH.
Summary · context
Twenty-five RCTs involving 2600 patients who used GLP-1RAs including liraglutide, exenatide, dulaglutide, semaglutide, tirzepatide, efinopegdutide, survodutide, and retatrutide were included.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4048958106
08HumanNot a test of Tirzepatide aloneSystematic reviewEfficacy outcome
In patients with MASLD or MASH, pooled GLP-1RAs (including tirzepatide) significantly improved histological steatosis.
In plain wordsIn people with fatty liver disease, GLP-1 drugs as a group, including tirzepatide, improved liver fat seen under the microscope.
Peptide
Tirzepatide
Outcome
DecreaseHistological steatosis
Study
n = 2,600
Outcome group
Liver fat and liver function · Liver
Source sentences
Summary
GLP-1RAs treatment induced significant histological improvements in steatosis, hepatocellular ballooning, and lobular inflammation
2 context sentences(design, population, supporting numbers)
Summary · context
We searched PubMed, Embase, and Cochrane Library databases to identify randomized controlled trials (RCTs) that compared GLP-1RAs with placebo or active agents with respect to the efficacy in patients with MASLD/MASH.
Summary · context
Twenty-five RCTs involving 2600 patients who used GLP-1RAs including liraglutide, exenatide, dulaglutide, semaglutide, tirzepatide, efinopegdutide, survodutide, and retatrutide were included.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4048958107
09HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In patients with MASLD or MASH, pooled GLP-1RAs (including semaglutide) significantly improved hepatocellular ballooning.
In plain wordsIn people with fatty liver disease, GLP-1 drugs as a group, including semaglutide, reduced swollen liver cells seen under the microscope.
Peptide
Semaglutide
Outcome
DecreaseHepatocellular ballooning
Study
n = 2,600
Outcome group
Liver fat and liver function · Liver
Source sentences
Summary
GLP-1RAs treatment induced significant histological improvements in steatosis, hepatocellular ballooning, and lobular inflammation
2 context sentences(design, population, supporting numbers)
Summary · context
We searched PubMed, Embase, and Cochrane Library databases to identify randomized controlled trials (RCTs) that compared GLP-1RAs with placebo or active agents with respect to the efficacy in patients with MASLD/MASH.
Summary · context
Twenty-five RCTs involving 2600 patients who used GLP-1RAs including liraglutide, exenatide, dulaglutide, semaglutide, tirzepatide, efinopegdutide, survodutide, and retatrutide were included.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4048958108
10HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In patients with MASLD or MASH, pooled GLP-1RAs (including liraglutide) significantly improved hepatocellular ballooning.
In plain wordsIn people with fatty liver disease, GLP-1 drugs as a group, including liraglutide, reduced swollen liver cells seen under the microscope.
Peptide
Liraglutide
Outcome
DecreaseHepatocellular ballooning
Study
n = 2,600
Outcome group
Liver fat and liver function · Liver
Source sentences
Summary
GLP-1RAs treatment induced significant histological improvements in steatosis, hepatocellular ballooning, and lobular inflammation
2 context sentences(design, population, supporting numbers)
Summary · context
We searched PubMed, Embase, and Cochrane Library databases to identify randomized controlled trials (RCTs) that compared GLP-1RAs with placebo or active agents with respect to the efficacy in patients with MASLD/MASH.
Summary · context
Twenty-five RCTs involving 2600 patients who used GLP-1RAs including liraglutide, exenatide, dulaglutide, semaglutide, tirzepatide, efinopegdutide, survodutide, and retatrutide were included.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4048958109
11HumanNot a test of Tirzepatide aloneSystematic reviewEfficacy outcome
In patients with MASLD or MASH, pooled GLP-1RAs (including tirzepatide) significantly improved hepatocellular ballooning.
In plain wordsIn people with fatty liver disease, GLP-1 drugs as a group, including tirzepatide, reduced swollen liver cells seen under the microscope.
Peptide
Tirzepatide
Outcome
DecreaseHepatocellular ballooning
Study
n = 2,600
Outcome group
Liver fat and liver function · Liver
Source sentences
Summary
GLP-1RAs treatment induced significant histological improvements in steatosis, hepatocellular ballooning, and lobular inflammation
2 context sentences(design, population, supporting numbers)
Summary · context
We searched PubMed, Embase, and Cochrane Library databases to identify randomized controlled trials (RCTs) that compared GLP-1RAs with placebo or active agents with respect to the efficacy in patients with MASLD/MASH.
Summary · context
Twenty-five RCTs involving 2600 patients who used GLP-1RAs including liraglutide, exenatide, dulaglutide, semaglutide, tirzepatide, efinopegdutide, survodutide, and retatrutide were included.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4048958110
12HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In patients with MASLD or MASH, pooled GLP-1RAs (including semaglutide) significantly improved lobular inflammation.
In plain wordsIn people with fatty liver disease, GLP-1 drugs as a group, including semaglutide, reduced liver inflammation seen under the microscope.
Peptide
Semaglutide
Outcome
DecreaseLobular inflammation
Study
n = 2,600
Outcome group
Liver fat and liver function · Liver
Source sentences
Summary
GLP-1RAs treatment induced significant histological improvements in steatosis, hepatocellular ballooning, and lobular inflammation
2 context sentences(design, population, supporting numbers)
Summary · context
We searched PubMed, Embase, and Cochrane Library databases to identify randomized controlled trials (RCTs) that compared GLP-1RAs with placebo or active agents with respect to the efficacy in patients with MASLD/MASH.
Summary · context
Twenty-five RCTs involving 2600 patients who used GLP-1RAs including liraglutide, exenatide, dulaglutide, semaglutide, tirzepatide, efinopegdutide, survodutide, and retatrutide were included.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4048958111
13HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In patients with MASLD or MASH, pooled GLP-1RAs (including liraglutide) significantly improved lobular inflammation.
In plain wordsIn people with fatty liver disease, GLP-1 drugs as a group, including liraglutide, reduced liver inflammation seen under the microscope.
Peptide
Liraglutide
Outcome
DecreaseLobular inflammation
Study
n = 2,600
Outcome group
Liver fat and liver function · Liver
Source sentences
Summary
GLP-1RAs treatment induced significant histological improvements in steatosis, hepatocellular ballooning, and lobular inflammation
2 context sentences(design, population, supporting numbers)
Summary · context
We searched PubMed, Embase, and Cochrane Library databases to identify randomized controlled trials (RCTs) that compared GLP-1RAs with placebo or active agents with respect to the efficacy in patients with MASLD/MASH.
Summary · context
Twenty-five RCTs involving 2600 patients who used GLP-1RAs including liraglutide, exenatide, dulaglutide, semaglutide, tirzepatide, efinopegdutide, survodutide, and retatrutide were included.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4048958112
14HumanNot a test of Tirzepatide aloneSystematic reviewEfficacy outcome
In patients with MASLD or MASH, pooled GLP-1RAs (including tirzepatide) significantly improved lobular inflammation.
In plain wordsIn people with fatty liver disease, GLP-1 drugs as a group, including tirzepatide, reduced liver inflammation seen under the microscope.
Peptide
Tirzepatide
Outcome
DecreaseLobular inflammation
Study
n = 2,600
Outcome group
Liver fat and liver function · Liver
Source sentences
Summary
GLP-1RAs treatment induced significant histological improvements in steatosis, hepatocellular ballooning, and lobular inflammation
2 context sentences(design, population, supporting numbers)
Summary · context
We searched PubMed, Embase, and Cochrane Library databases to identify randomized controlled trials (RCTs) that compared GLP-1RAs with placebo or active agents with respect to the efficacy in patients with MASLD/MASH.
Summary · context
Twenty-five RCTs involving 2600 patients who used GLP-1RAs including liraglutide, exenatide, dulaglutide, semaglutide, tirzepatide, efinopegdutide, survodutide, and retatrutide were included.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4048958113
15HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In patients with MASLD or MASH, pooled GLP-1RAs (including semaglutide) improved fibrosis only nonsignificantly.
In plain wordsIn people with fatty liver disease, GLP-1 drugs as a group, including semaglutide, did not significantly improve liver scarring.
Peptide
Semaglutide
Outcome
No significant changeHistological fibrosis
Study
n = 2,600
Outcome group
Liver fat and liver function · Liver
Source sentences
Summary
nonsignificantly improved fibrosis
2 context sentences(design, population, supporting numbers)
Summary · context
We searched PubMed, Embase, and Cochrane Library databases to identify randomized controlled trials (RCTs) that compared GLP-1RAs with placebo or active agents with respect to the efficacy in patients with MASLD/MASH.
Summary · context
Twenty-five RCTs involving 2600 patients who used GLP-1RAs including liraglutide, exenatide, dulaglutide, semaglutide, tirzepatide, efinopegdutide, survodutide, and retatrutide were included.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4048958114
16HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In patients with MASLD or MASH, pooled GLP-1RAs (including liraglutide) improved fibrosis only nonsignificantly.
In plain wordsIn people with fatty liver disease, GLP-1 drugs as a group, including liraglutide, did not significantly improve liver scarring.
Peptide
Liraglutide
Outcome
No significant changeHistological fibrosis
Study
n = 2,600
Outcome group
Liver fat and liver function · Liver
Source sentences
Summary
nonsignificantly improved fibrosis
2 context sentences(design, population, supporting numbers)
Summary · context
We searched PubMed, Embase, and Cochrane Library databases to identify randomized controlled trials (RCTs) that compared GLP-1RAs with placebo or active agents with respect to the efficacy in patients with MASLD/MASH.
Summary · context
Twenty-five RCTs involving 2600 patients who used GLP-1RAs including liraglutide, exenatide, dulaglutide, semaglutide, tirzepatide, efinopegdutide, survodutide, and retatrutide were included.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4048958115
17HumanNot a test of Tirzepatide aloneSystematic reviewEfficacy outcome
In patients with MASLD or MASH, pooled GLP-1RAs (including tirzepatide) improved fibrosis only nonsignificantly.
In plain wordsIn people with fatty liver disease, GLP-1 drugs as a group, including tirzepatide, did not significantly improve liver scarring.
Peptide
Tirzepatide
Outcome
No significant changeHistological fibrosis
Study
n = 2,600
Outcome group
Liver fat and liver function · Liver
Source sentences
Summary
nonsignificantly improved fibrosis
2 context sentences(design, population, supporting numbers)
Summary · context
We searched PubMed, Embase, and Cochrane Library databases to identify randomized controlled trials (RCTs) that compared GLP-1RAs with placebo or active agents with respect to the efficacy in patients with MASLD/MASH.
Summary · context
Twenty-five RCTs involving 2600 patients who used GLP-1RAs including liraglutide, exenatide, dulaglutide, semaglutide, tirzepatide, efinopegdutide, survodutide, and retatrutide were included.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4048958116
18HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In patients with MASLD or MASH, pooled GLP-1RAs (including semaglutide) significantly decreased serum ALT versus control.
In plain wordsIn people with fatty liver disease, GLP-1 drugs as a group, including semaglutide, lowered the liver enzyme ALT compared with control.
Peptide
Semaglutide
Outcome
DecreaseSerum alanine aminotransferase
Study
n = 2,600
Comparator
Control
Outcome group
Liver fat and liver function · Liver
Source sentences
Summary
GLP-1RAs treatment significantly decreased serum alanine aminotransferase, aspartate aminotransferase, and γ-glutamyl transferase compared with control.
2 context sentences(design, population, supporting numbers)
Summary · context
We searched PubMed, Embase, and Cochrane Library databases to identify randomized controlled trials (RCTs) that compared GLP-1RAs with placebo or active agents with respect to the efficacy in patients with MASLD/MASH.
Summary · context
Twenty-five RCTs involving 2600 patients who used GLP-1RAs including liraglutide, exenatide, dulaglutide, semaglutide, tirzepatide, efinopegdutide, survodutide, and retatrutide were included.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4048958117
19HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In patients with MASLD or MASH, pooled GLP-1RAs (including liraglutide) significantly decreased serum ALT versus control.
In plain wordsIn people with fatty liver disease, GLP-1 drugs as a group, including liraglutide, lowered the liver enzyme ALT compared with control.
Peptide
Liraglutide
Outcome
DecreaseSerum alanine aminotransferase
Study
n = 2,600
Comparator
Control
Outcome group
Liver fat and liver function · Liver
Source sentences
Summary
GLP-1RAs treatment significantly decreased serum alanine aminotransferase, aspartate aminotransferase, and γ-glutamyl transferase compared with control.
2 context sentences(design, population, supporting numbers)
Summary · context
We searched PubMed, Embase, and Cochrane Library databases to identify randomized controlled trials (RCTs) that compared GLP-1RAs with placebo or active agents with respect to the efficacy in patients with MASLD/MASH.
Summary · context
Twenty-five RCTs involving 2600 patients who used GLP-1RAs including liraglutide, exenatide, dulaglutide, semaglutide, tirzepatide, efinopegdutide, survodutide, and retatrutide were included.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4048958118
20HumanNot a test of Tirzepatide aloneSystematic reviewEfficacy outcome
In patients with MASLD or MASH, pooled GLP-1RAs (including tirzepatide) significantly decreased serum ALT versus control.
In plain wordsIn people with fatty liver disease, GLP-1 drugs as a group, including tirzepatide, lowered the liver enzyme ALT compared with control.
Peptide
Tirzepatide
Outcome
DecreaseSerum alanine aminotransferase
Study
n = 2,600
Comparator
Control
Outcome group
Liver fat and liver function · Liver
Source sentences
Summary
GLP-1RAs treatment significantly decreased serum alanine aminotransferase, aspartate aminotransferase, and γ-glutamyl transferase compared with control.
2 context sentences(design, population, supporting numbers)
Summary · context
We searched PubMed, Embase, and Cochrane Library databases to identify randomized controlled trials (RCTs) that compared GLP-1RAs with placebo or active agents with respect to the efficacy in patients with MASLD/MASH.
Summary · context
Twenty-five RCTs involving 2600 patients who used GLP-1RAs including liraglutide, exenatide, dulaglutide, semaglutide, tirzepatide, efinopegdutide, survodutide, and retatrutide were included.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4048958119
21HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In patients with MASLD or MASH, pooled GLP-1RAs (including semaglutide) significantly decreased serum AST versus control.
In plain wordsIn people with fatty liver disease, GLP-1 drugs as a group, including semaglutide, lowered the liver enzyme AST compared with control.
Peptide
Semaglutide
Outcome
DecreaseSerum aspartate aminotransferase
Study
n = 2,600
Comparator
Control
Outcome group
Liver fat and liver function · Liver
Source sentences
Summary
GLP-1RAs treatment significantly decreased serum alanine aminotransferase, aspartate aminotransferase, and γ-glutamyl transferase compared with control.
2 context sentences(design, population, supporting numbers)
Summary · context
We searched PubMed, Embase, and Cochrane Library databases to identify randomized controlled trials (RCTs) that compared GLP-1RAs with placebo or active agents with respect to the efficacy in patients with MASLD/MASH.
Summary · context
Twenty-five RCTs involving 2600 patients who used GLP-1RAs including liraglutide, exenatide, dulaglutide, semaglutide, tirzepatide, efinopegdutide, survodutide, and retatrutide were included.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4048958120
22HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In patients with MASLD or MASH, pooled GLP-1RAs (including liraglutide) significantly decreased serum AST versus control.
In plain wordsIn people with fatty liver disease, GLP-1 drugs as a group, including liraglutide, lowered the liver enzyme AST compared with control.
Peptide
Liraglutide
Outcome
DecreaseSerum aspartate aminotransferase
Study
n = 2,600
Comparator
Control
Outcome group
Liver fat and liver function · Liver
Source sentences
Summary
GLP-1RAs treatment significantly decreased serum alanine aminotransferase, aspartate aminotransferase, and γ-glutamyl transferase compared with control.
2 context sentences(design, population, supporting numbers)
Summary · context
We searched PubMed, Embase, and Cochrane Library databases to identify randomized controlled trials (RCTs) that compared GLP-1RAs with placebo or active agents with respect to the efficacy in patients with MASLD/MASH.
Summary · context
Twenty-five RCTs involving 2600 patients who used GLP-1RAs including liraglutide, exenatide, dulaglutide, semaglutide, tirzepatide, efinopegdutide, survodutide, and retatrutide were included.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4048958121
23HumanNot a test of Tirzepatide aloneSystematic reviewEfficacy outcome
In patients with MASLD or MASH, pooled GLP-1RAs (including tirzepatide) significantly decreased serum AST versus control.
In plain wordsIn people with fatty liver disease, GLP-1 drugs as a group, including tirzepatide, lowered the liver enzyme AST compared with control.
Peptide
Tirzepatide
Outcome
DecreaseSerum aspartate aminotransferase
Study
n = 2,600
Comparator
Control
Outcome group
Liver fat and liver function · Liver
Source sentences
Summary
GLP-1RAs treatment significantly decreased serum alanine aminotransferase, aspartate aminotransferase, and γ-glutamyl transferase compared with control.
2 context sentences(design, population, supporting numbers)
Summary · context
We searched PubMed, Embase, and Cochrane Library databases to identify randomized controlled trials (RCTs) that compared GLP-1RAs with placebo or active agents with respect to the efficacy in patients with MASLD/MASH.
Summary · context
Twenty-five RCTs involving 2600 patients who used GLP-1RAs including liraglutide, exenatide, dulaglutide, semaglutide, tirzepatide, efinopegdutide, survodutide, and retatrutide were included.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4048958122
24HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In patients with MASLD or MASH, pooled GLP-1RAs (including semaglutide) significantly decreased serum GGT versus control.
In plain wordsIn people with fatty liver disease, GLP-1 drugs as a group, including semaglutide, lowered the liver enzyme GGT compared with control.
Peptide
Semaglutide
Outcome
DecreaseSerum gamma-glutamyl transferase
Study
n = 2,600
Comparator
Control
Outcome group
Liver fat and liver function · Liver
Source sentences
Summary
GLP-1RAs treatment significantly decreased serum alanine aminotransferase, aspartate aminotransferase, and γ-glutamyl transferase compared with control.
2 context sentences(design, population, supporting numbers)
Summary · context
We searched PubMed, Embase, and Cochrane Library databases to identify randomized controlled trials (RCTs) that compared GLP-1RAs with placebo or active agents with respect to the efficacy in patients with MASLD/MASH.
Summary · context
Twenty-five RCTs involving 2600 patients who used GLP-1RAs including liraglutide, exenatide, dulaglutide, semaglutide, tirzepatide, efinopegdutide, survodutide, and retatrutide were included.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4048958123
25HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In patients with MASLD or MASH, pooled GLP-1RAs (including liraglutide) significantly decreased serum GGT versus control.
In plain wordsIn people with fatty liver disease, GLP-1 drugs as a group, including liraglutide, lowered the liver enzyme GGT compared with control.
Peptide
Liraglutide
Outcome
DecreaseSerum gamma-glutamyl transferase
Study
n = 2,600
Comparator
Control
Outcome group
Liver fat and liver function · Liver
Source sentences
Summary
GLP-1RAs treatment significantly decreased serum alanine aminotransferase, aspartate aminotransferase, and γ-glutamyl transferase compared with control.
2 context sentences(design, population, supporting numbers)
Summary · context
We searched PubMed, Embase, and Cochrane Library databases to identify randomized controlled trials (RCTs) that compared GLP-1RAs with placebo or active agents with respect to the efficacy in patients with MASLD/MASH.
Summary · context
Twenty-five RCTs involving 2600 patients who used GLP-1RAs including liraglutide, exenatide, dulaglutide, semaglutide, tirzepatide, efinopegdutide, survodutide, and retatrutide were included.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4048958124
26HumanNot a test of Tirzepatide aloneSystematic reviewEfficacy outcome
In patients with MASLD or MASH, pooled GLP-1RAs (including tirzepatide) significantly decreased serum GGT versus control.
In plain wordsIn people with fatty liver disease, GLP-1 drugs as a group, including tirzepatide, lowered the liver enzyme GGT compared with control.
Peptide
Tirzepatide
Outcome
DecreaseSerum gamma-glutamyl transferase
Study
n = 2,600
Comparator
Control
Outcome group
Liver fat and liver function · Liver
Source sentences
Summary
GLP-1RAs treatment significantly decreased serum alanine aminotransferase, aspartate aminotransferase, and γ-glutamyl transferase compared with control.
2 context sentences(design, population, supporting numbers)
Summary · context
We searched PubMed, Embase, and Cochrane Library databases to identify randomized controlled trials (RCTs) that compared GLP-1RAs with placebo or active agents with respect to the efficacy in patients with MASLD/MASH.
Summary · context
Twenty-five RCTs involving 2600 patients who used GLP-1RAs including liraglutide, exenatide, dulaglutide, semaglutide, tirzepatide, efinopegdutide, survodutide, and retatrutide were included.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4048958125
27HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In patients with MASLD or MASH, pooled GLP-1RAs (including semaglutide) significantly improved liver stiffness.
In plain wordsIn people with fatty liver disease, GLP-1 drugs as a group, including semaglutide, reduced liver stiffness.
Peptide
Semaglutide
Outcome
DecreaseLiver stiffness
Study
n = 2,600
Outcome group
Liver fat and liver function · Liver
Source sentences
Summary
GLP-1RAs also significantly improved liver stiffness
2 context sentences(design, population, supporting numbers)
Summary · context
We searched PubMed, Embase, and Cochrane Library databases to identify randomized controlled trials (RCTs) that compared GLP-1RAs with placebo or active agents with respect to the efficacy in patients with MASLD/MASH.
Summary · context
Twenty-five RCTs involving 2600 patients who used GLP-1RAs including liraglutide, exenatide, dulaglutide, semaglutide, tirzepatide, efinopegdutide, survodutide, and retatrutide were included.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4048958126
28HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In patients with MASLD or MASH, pooled GLP-1RAs (including liraglutide) significantly improved liver stiffness.
In plain wordsIn people with fatty liver disease, GLP-1 drugs as a group, including liraglutide, reduced liver stiffness.
Peptide
Liraglutide
Outcome
DecreaseLiver stiffness
Study
n = 2,600
Outcome group
Liver fat and liver function · Liver
Source sentences
Summary
GLP-1RAs also significantly improved liver stiffness
2 context sentences(design, population, supporting numbers)
Summary · context
We searched PubMed, Embase, and Cochrane Library databases to identify randomized controlled trials (RCTs) that compared GLP-1RAs with placebo or active agents with respect to the efficacy in patients with MASLD/MASH.
Summary · context
Twenty-five RCTs involving 2600 patients who used GLP-1RAs including liraglutide, exenatide, dulaglutide, semaglutide, tirzepatide, efinopegdutide, survodutide, and retatrutide were included.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4048958127
29HumanNot a test of Tirzepatide aloneSystematic reviewEfficacy outcome
In patients with MASLD or MASH, pooled GLP-1RAs (including tirzepatide) significantly improved liver stiffness.
In plain wordsIn people with fatty liver disease, GLP-1 drugs as a group, including tirzepatide, reduced liver stiffness.
Peptide
Tirzepatide
Outcome
DecreaseLiver stiffness
Study
n = 2,600
Outcome group
Liver fat and liver function · Liver
Source sentences
Summary
GLP-1RAs also significantly improved liver stiffness
2 context sentences(design, population, supporting numbers)
Summary · context
We searched PubMed, Embase, and Cochrane Library databases to identify randomized controlled trials (RCTs) that compared GLP-1RAs with placebo or active agents with respect to the efficacy in patients with MASLD/MASH.
Summary · context
Twenty-five RCTs involving 2600 patients who used GLP-1RAs including liraglutide, exenatide, dulaglutide, semaglutide, tirzepatide, efinopegdutide, survodutide, and retatrutide were included.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4048958128
30HumanNot a test of Semaglutide aloneSystematic reviewSafety outcome
In patients with MASLD or MASH, no drug-related liver adverse effects were observed with pooled GLP-1RAs (including semaglutide).
In plain wordsIn people with fatty liver disease, no drug-related liver side effects were seen with GLP-1 drugs as a group, including semaglutide.
Peptide
Semaglutide
Outcome
No significant changeDrug-related liver adverse effects
Study
n = 2,600
Outcome group
Adverse events · Liver
Source sentences
Summary
No drug-related adverse effects involving the liver were observed.
2 context sentences(design, population, supporting numbers)
Summary · context
We searched PubMed, Embase, and Cochrane Library databases to identify randomized controlled trials (RCTs) that compared GLP-1RAs with placebo or active agents with respect to the efficacy in patients with MASLD/MASH.
Summary · context
Twenty-five RCTs involving 2600 patients who used GLP-1RAs including liraglutide, exenatide, dulaglutide, semaglutide, tirzepatide, efinopegdutide, survodutide, and retatrutide were included.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4048958130
31HumanNot a test of Liraglutide aloneSystematic reviewSafety outcome
In patients with MASLD or MASH, no drug-related liver adverse effects were observed with pooled GLP-1RAs (including liraglutide).
In plain wordsIn people with fatty liver disease, no drug-related liver side effects were seen with GLP-1 drugs as a group, including liraglutide.
Peptide
Liraglutide
Outcome
No significant changeDrug-related liver adverse effects
Study
n = 2,600
Outcome group
Adverse events · Liver
Source sentences
Summary
No drug-related adverse effects involving the liver were observed.
2 context sentences(design, population, supporting numbers)
Summary · context
We searched PubMed, Embase, and Cochrane Library databases to identify randomized controlled trials (RCTs) that compared GLP-1RAs with placebo or active agents with respect to the efficacy in patients with MASLD/MASH.
Summary · context
Twenty-five RCTs involving 2600 patients who used GLP-1RAs including liraglutide, exenatide, dulaglutide, semaglutide, tirzepatide, efinopegdutide, survodutide, and retatrutide were included.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4048958131
32HumanNot a test of Tirzepatide aloneSystematic reviewSafety outcome
In patients with MASLD or MASH, no drug-related liver adverse effects were observed with pooled GLP-1RAs (including tirzepatide).
In plain wordsIn people with fatty liver disease, no drug-related liver side effects were seen with GLP-1 drugs as a group, including tirzepatide.
Peptide
Tirzepatide
Outcome
No significant changeDrug-related liver adverse effects
Study
n = 2,600
Outcome group
Adverse events · Liver
Source sentences
Summary
No drug-related adverse effects involving the liver were observed.
2 context sentences(design, population, supporting numbers)
Summary · context
We searched PubMed, Embase, and Cochrane Library databases to identify randomized controlled trials (RCTs) that compared GLP-1RAs with placebo or active agents with respect to the efficacy in patients with MASLD/MASH.
Summary · context
Twenty-five RCTs involving 2600 patients who used GLP-1RAs including liraglutide, exenatide, dulaglutide, semaglutide, tirzepatide, efinopegdutide, survodutide, and retatrutide were included.
In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.
Report a problemFND-4048958132

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Versions 6 to 41Current
28 Oct 2026, 02:04 UTC
The same notice was added 36 times, first on 9 Oct 2026, 19:08 UTC. The status did not change between them.
Study results updated
Versions 2 to 5
9 Oct 2026, 03:07 UTC
The same notice was added 4 times, first on 9 Oct 2026, 03:05 UTC. The status did not change between them.
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:04 UTC
First added · source update from Europe PMC

Efficacy of GLP-1-based Therapies on Metabolic Dysfunction-associated Steatotic Liver Disease and Metabolic Dysfunction-associated Steatohepatitis: A Systematic Review and Meta-analysis.

Summary

Results from this study32

Studies that did not test the peptide alone30

Version history

Subjects

Publication types

MeSH terms

Keywords